SGLT2i, Canagliflozin mitigates amyloid‐beta pathology and cognitive decline in 5XFAD mice

Abstract

Background: Aging is the primary risk factor for numerous chronic diseases, including neurodegenerative disorders such as Alzheimer’s disease (AD). Current therapeutic options for AD provide limited efficacy, thus requiring novel interventions that target key molecular pathways associated with aging and neurodegeneration.